Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Expected to Post Quarterly Sales of $192.62 Million

Equities research analysts expect Sarepta Therapeutics, Inc. (NASDAQ:SRPT) to report sales of $192.62 million for the current fiscal quarter, according to Zacks Investment Research. Five analysts have provided estimates for Sarepta Therapeutics’ earnings. The lowest sales estimate is $175.25 million and the highest is $201.70 million. Sarepta Therapeutics posted sales of $145.14 million during the same quarter last year, which suggests a positive year over year growth rate of 32.7%. The company is expected to issue its next quarterly earnings report on Monday, March 7th.

On average, analysts expect that Sarepta Therapeutics will report full-year sales of $670.87 million for the current year, with estimates ranging from $622.91 million to $702.20 million. For the next financial year, analysts anticipate that the firm will post sales of $867.34 million, with estimates ranging from $754.72 million to $956.60 million. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that follow Sarepta Therapeutics.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings data on Wednesday, November 3rd. The biotechnology company reported ($0.60) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.86) by $1.26. The company had revenue of $189.41 million for the quarter, compared to analysts’ expectations of $170.13 million. Sarepta Therapeutics had a negative net margin of 75.30% and a negative return on equity of 86.35%. During the same quarter in the previous year, the company posted ($2.50) EPS.

SRPT has been the subject of several recent analyst reports. Needham & Company LLC decreased their target price on shares of Sarepta Therapeutics from $166.00 to $157.00 and set a “buy” rating for the company in a report on Thursday, November 4th. Guggenheim upgraded shares of Sarepta Therapeutics from a “neutral” rating to a “buy” rating in a report on Wednesday, September 15th. Robert W. Baird initiated coverage on shares of Sarepta Therapeutics in a report on Thursday, October 7th. They issued a “buy” rating and a $110.00 target price for the company. JPMorgan Chase & Co. upgraded shares of Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and raised their target price for the stock from $88.00 to $130.00 in a report on Friday, November 5th. Finally, Cantor Fitzgerald raised their target price on shares of Sarepta Therapeutics from $128.00 to $140.00 and gave the stock an “overweight” rating in a report on Thursday, November 4th. Ten research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to MarketBeat, Sarepta Therapeutics has a consensus rating of “Buy” and a consensus target price of $126.41.

In other Sarepta Therapeutics news, CEO Douglas S. Ingram acquired 25,026 shares of the business’s stock in a transaction that occurred on Wednesday, November 17th. The shares were purchased at an average price of $79.94 per share, with a total value of $2,000,578.44. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 5.90% of the stock is currently owned by company insiders.

A number of institutional investors and hedge funds have recently modified their holdings of SRPT. Amundi Pioneer Asset Management Inc. raised its position in Sarepta Therapeutics by 32.8% during the first quarter. Amundi Pioneer Asset Management Inc. now owns 154,611 shares of the biotechnology company’s stock valued at $18,428,000 after acquiring an additional 38,194 shares in the last quarter. California State Teachers Retirement System raised its position in shares of Sarepta Therapeutics by 0.6% in the first quarter. California State Teachers Retirement System now owns 141,889 shares of the biotechnology company’s stock valued at $10,575,000 after purchasing an additional 855 shares during the period. Tudor Investment Corp Et Al raised its position in shares of Sarepta Therapeutics by 130.6% in the first quarter. Tudor Investment Corp Et Al now owns 6,484 shares of the biotechnology company’s stock valued at $483,000 after purchasing an additional 3,672 shares during the period. Amundi Asset Management US Inc. raised its position in shares of Sarepta Therapeutics by 29.4% in the first quarter. Amundi Asset Management US Inc. now owns 52,928 shares of the biotechnology company’s stock valued at $3,944,000 after purchasing an additional 12,027 shares during the period. Finally, Eaton Vance Management bought a new position in shares of Sarepta Therapeutics in the first quarter valued at approximately $137,000. 78.17% of the stock is currently owned by hedge funds and other institutional investors.

Shares of SRPT traded up $1.65 during mid-day trading on Monday, hitting $80.98. The company’s stock had a trading volume of 415,328 shares, compared to its average volume of 1,315,641. Sarepta Therapeutics has a fifty-two week low of $65.30 and a fifty-two week high of $181.83. The firm has a 50-day moving average price of $85.86 and a 200 day moving average price of $79.51. The stock has a market capitalization of $7.05 billion, a price-to-earnings ratio of -13.23 and a beta of 1.21. The company has a debt-to-equity ratio of 2.33, a current ratio of 5.85 and a quick ratio of 5.08.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Featured Article: Rule of 72

Get a free copy of the Zacks research report on Sarepta Therapeutics (SRPT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.